William ('Bill') Lambert Email Address

Pharmaceutical Development, CMC, and Drug Delivery Consultant

Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Part of its proprietary PharmacoSurgery platform, the company's first drug product, OMIDRIA (phenylephrine and ketorolac injection) 1% / 0.3%, was broadly launched in the U.S. in April 2015. OMIDRIA is the first and only FDA-approved drug (1) for use during cataract surgery or intraocular lens (IOL) replacement to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain and (2) that contains an NSAID for intraocular use. In the European Union, the European Commission has approved OMIDRIA for use in cataract surgery and lens replacement procedures to maintain mydriasis (pupil dilation), prevent miosis (pupil constriction), and to reduce postoperative eye pain. Omeros has clinical-stage development programs focused on: complement-associated thrombotic microangiopathies| complement-mediated glomerulonephropathies| Huntington's disease and cognitive impairment| and addictive and compulsive disorders. In addition, Omeros has a proprietary G protein-coupled receptor (GPCR) platform, which is making available an unprecedented number of new GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development, and a platform used to generate antibodies.

Dr. Lambert is currently Vice President, Chemistry, Manufacturing, and Control at Omeros Corporation, a Seattle-based biopharmaceutical company committed to discovering, developing, and commercializing small-molecule and protein therapeutics targeting inflammation, coagulopathies, and disorders of the central nervous system. Prior to Omeros, he headed the Innovative Drug Delivery Group at MedImmune / AstraZeneca. He was Sr. VP of Pharmaceutical Development at Pacira Pharmaceuticals. He also directed drug delivery, product development, and cGMP clinical supply groups at Eisai Inc. in RTP, NC. He held various positions at Pfizer where his group was responsible for formulations of human and animal drug candidates. In addition, he worked in the areas of preformulation, sterile product development and biotechnology drug delivery at the Upjohn Company. In the above positions, he contributed to the development and registration efforts of several marketed drugs including Corvert (anti-arrhythmic), Trovan (antibiotic), Halaven (anti-cancer), and Exparel (post-surgical pain). Dr. Lambert received his B.S. in Pharmacy from the Univ. of RI followed by graduate studies in Pharmaceutics at the Univ. of Michigan and Utah. He was an NPC Intern at Lederle Laboratories, a Pharmacy Research Summer Scholar at The Upjohn Company, and a recipient of the J.K. Lilly Memorial Fellowship. He teaches a course on dosage form design and development at UCSD Extension and was an invited guest editor for an AAPS PharmSciTech themed issue in 2010. He has over 25 peer reviewed publications, is a member of the Advisory Boards of J. Pharm. Sci., NIPTE, AFPE, Handbook of Pharm Excipients, USP Excipient Expert Comm, and is past chair of the Pharm Tech Section of the AAPS. Specialties: Formulation Devel Analytical Devel Tech Transfer Preclinical Testing Drug Delivery Combination Product Devices GMP CMC Regulatory Life Cycle Management